Sodium Bicarbonate for Metabolic Acidosis in the Intensive Care Unit (SODa-BIC) trial
For critically ill patients with metabolic acidosis and vasopressor dependence, the current evidence from SODa-BIC suggests caution before routine bicarbonate administration. Remember that while some prior work suggested a benefit regarding renal replacement therapy use, the overall impact on major adverse kidney events needs careful interpretation in practice. Always consider the underlying cause of the acidosis when deciding on alkali supplementation.
The SODa-BIC trial addressed a persistent question in critical care: whether administering sodium bicarbonate to critically ill patients with metabolic acidosis and concurrent vasopressor support actually improves kidney outcomes. This multi-center, randomized controlled trial specifically enrolled adults meeting criteria for metabolic acidosis (pH < 7.30) while requiring vasoactive agents. The primary endpoint was the reduction of major adverse kidney events within a 30-day window. While the abstract notes that prior literature presented conflicting data regarding bicarbonate's role in renal protection, this large trial provided updated evidence on the topic.